Tower Research Capital LLC (Trc) Macrogenics Inc Transaction History

Tower Research Capital LLC (Trc)

$3.68 Billion
Q3 2024

A detailed history of Tower Research Capital LLC (Trc) transactions in Macrogenics Inc stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 2,987 shares of MGNX stock, worth $9,737. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,987

Previous 17,344 82.78%

Holding current value

$9,737

Previous $73,000 87.67%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.0 - $5.55 $43,071 - $79,681	-14,357 Reduced 82.78%	2,987 $9,000
Q2 2024 Aug 13, 2024	BUY	$3.31 - $18.51 $47,531 - $265,803	14,360 Added 481.23%	17,344 $73,000
Q1 2024 May 15, 2024	SELL	$9.77 - $21.47 $208,892 - $459,050	-21,381 Reduced 87.75%	2,984 $43,000
Q4 2023 Feb 13, 2024	BUY	$4.48 - $10.11 $70,967 - $160,152	15,841 Added 185.84%	24,365 $234,000
Q3 2023 Nov 14, 2023	BUY	$4.48 - $6.19 $16,253 - $22,457	3,628 Added 74.1%	8,524 $39,000
Q2 2023 Aug 14, 2023	BUY	$4.62 - $7.54 $4,070 - $6,642	881 Added 21.94%	4,896 $26,000
Q1 2023 May 09, 2023	BUY	$4.82 - $7.24 $2,843 - $4,271	590 Added 17.23%	4,015 $29,000
Q4 2022 Feb 10, 2023	SELL	$3.34 - $6.98 $2,171 - $4,537	-650 Reduced 15.95%	3,425 $23,000
Q3 2022 Nov 10, 2022	SELL	$3.01 - $5.22 $61,954 - $107,443	-20,583 Reduced 83.47%	4,075 $14,000
Q2 2022 Aug 15, 2022	BUY	$2.25 - $9.99 $18,607 - $82,617	8,270 Added 50.46%	24,658 $73,000
Q1 2022 May 12, 2022	BUY	$8.12 - $16.9 $61,598 - $128,203	7,586 Added 86.18%	16,388 $145,000
Q4 2021 Feb 14, 2022	BUY	$15.91 - $21.88 $50,005 - $68,768	3,143 Added 55.54%	8,802 $142,000
Q3 2021 Nov 15, 2021	BUY	$19.74 - $28.7 $42,342 - $61,561	2,145 Added 61.04%	5,659 $118,000
Q2 2021 Aug 16, 2021	SELL	$20.49 - $35.63 $9,589 - $16,674	-468 Reduced 11.75%	3,514 $94,000
Q1 2021 May 17, 2021	BUY	$18.99 - $33.2 $51,519 - $90,071	2,713 Added 213.79%	3,982 $127,000
Q4 2020 Feb 16, 2021	SELL	$19.41 - $26.0 $18,536 - $24,830	-955 Reduced 42.94%	1,269 $29,000
Q3 2020 Nov 16, 2020	SELL	$24.69 - $31.6 $104,068 - $133,194	-4,215 Reduced 65.46%	2,224 $56,000
Q2 2020 Aug 13, 2020	BUY	$5.2 - $29.12 $33,482 - $187,503	6,439 New	6,439 $180,000
Q4 2019 Feb 07, 2020	SELL	$7.95 - $12.27 $58,623 - $90,478	-7,374 Closed	0 $0
Q3 2019 Nov 05, 2019	BUY	$12.44 - $17.48 $91,732 - $128,897	7,374 New	7,374 $94,000
Q2 2019 Aug 13, 2019	SELL	$14.51 - $19.71 $70,315 - $95,514	-4,846 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$11.11 - $25.6 $52,728 - $121,497	4,746 Added 4746.0%	4,846 $87,000
Q4 2018 Feb 14, 2019	BUY	$11.75 - $21.42 $1,175 - $2,142	100 New	100 $1,000
Q2 2018 Aug 15, 2018	SELL	$19.78 - $24.67 $13,035 - $16,257	-659 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$18.89 - $32.46 $2,417 - $4,154	-128 Reduced 16.26%	659 $17,000
Q4 2017 Feb 09, 2018	SELL	$16.19 - $20.3 $27,215 - $34,124	-1,681 Reduced 68.11%	787 $15,000
Q3 2017 Nov 14, 2017	BUY	$15.52 - $18.94 $38,303 - $46,743	2,468	2,468 $46,000

Others Institutions Holding MGNX

# of Institutions

132

Shares Held

55.4M

Call Options Held

215K

Put Options Held

238K

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.

Account

Tower Research Capital LLC (Trc) Macrogenics Inc Transaction History